Wegovy and Zepbound users across the state lost insurance coverage this year. A Boston endocrinologist warns lower-income patients are hit hardest.
Recap by typeshit. Full story at The Bay State Banner.
Fifteen drugs, from Ozempic and Wegovy to Trelegy Ellipta, get Medicare negotiated prices that take effect January 1, 2027.
Analysts led by Yang Huang expect about 15% yearly growth, citing the large diabetes and obesity burden across the three countries.
A guide covers who qualifies for the lower price, how to bring it up with a doctor, and delivery options that cut costs further.
A Facebook post says Ozempic's Medicare price drops 71% as negotiated rates on 15 drugs, including Wegovy and Trelegy, take effect.
In an ADJUST-T1D follow-up, former semaglutide users lost a median 3.6 points of time in range within 3 months, even while on automated insulin delivery.
With retatrutide trials showing losses near 29%, doctors quoted by Medscape describe when weight loss may be going too far and lost strength calls for a rethink.
Loading…